Preliminary results of a phase II study of alrizomadlin (APG-115), a novel, small-molecule MDM2 inhibitor, in combination with pembrolizumab in patients (pts) with unresectable or metastatic melanoma or advanced solid tumors that have failed immuno-oncologic (I-O) drugs.

Anthony W. Tolcher,James A. Reeves,Meredith McKean,Bartosz Chmielowski,Jt Beck,Montaser Shaheen,Neeta Somaiah,Melissa Wilson,Alexander I. Spira,Joseph J. Drabick,Yuefen Tang,Robert Winkler,Mingyu Li,Mohammad Ahmad,Ming Lu,Zhiyan Liang,Dajun Yang,Yifan Zhai

Preliminary results of a phase II study of alrizomadlin (APG-115), a novel, small-molecule MDM2 inhibitor, in combination with pembrolizumab in patients (pts) with unresectable or metastatic melanoma or advanced solid tumors that have failed immuno-oncologic (I-O) drugs.

2021

Anthony W. Tolcher
James A. Reeves
Meredith McKean
Bartosz Chmielowski
Jt Beck
Montaser Shaheen
Neeta Somaiah
Melissa Wilson
Alexander I. Spira
Joseph J. Drabick
Yuefen Tang
Robert Winkler
Mingyu Li
Mohammad Ahmad
Ming Lu
Zhiyan Liang
Dajun Yang
Yifan Zhai

2506Background: Alrizomadlin (APG-115) restores TP53 function, activating p53-mediated apoptosis in tumor cells with wild-type TP53 and/or MDM2 amplification. Alrizomadlin also functions as a host ...

Keywords:

Cancer research
in patient
Mdm2
metastatic melanoma
Medicine
Pembrolizumab
Small molecule
Apoptosis
tumor cells
Phases of clinical research

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations